03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
12:32 , Feb 27, 2018 |  BioCentury  |  Emerging Company Profile

Stressing out cancer

Quentis Therapeutics Inc. debuted with a $48 million series A round to develop potentially first-in-class therapies that inhibit the ER stress response, with the dual effect of killing tumor cells directly and unleashing immune cells...
07:00 , Mar 20, 2014 |  BC Innovations  |  Cover Story

A liver divided

Three separate teams have directly converted human fibroblasts to proliferative liver cells and thus eliminated a key drawback of using induced pluripotent stem cells to treat damaged livers-the inability of the resulting differentiated cells to...
07:00 , Jul 14, 2011 |  BC Innovations  |  Targets & Mechanisms

NOGO could go far

A team of U.S. and Canadian researchers has shown that blocking production of NOGO-B in pulmonary arteries could prevent the deleterious vascular remodeling seen in pulmonary arterial hypertension.1 If future studies demonstrate that NOGO-B inhibitors...
07:00 , Jul 9, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Type 2 diabetes; obesity ...